文献速递流行病学与生物统计

填补研究显示缺失结局数据可显著偏倚患者报告结局系统评价的合并估计

An imputation study shows that missing outcome data can substantially bias pooled estimates in systematic reviews of patient-reported outcomes.
PubMed 文献 · J Clin Epidemiol · 2025-12-27

该研究选取100篇包含对连续患者报告疗效结局有统计学显著效应的Meta分析的系统评价,应用基于GRADE的四种填补策略及三种替代方法。最不严格策略下仅不到4%的Meta分析95%CI跨过无效线,次严格策略下升至47.9%,最严格策略下达54.2%。缺失数据比例越高、治疗效应越小,CI跨过无效线的可能性越大。

要点

  • 缺失结局数据可显著影响患者报告结局系统评价的合并效应估计。
  • 次严格填补策略下47.9%的Meta分析95%CI跨过无效线。
  • 缺失数据每增加1%,CI跨过无效线的OR为1.23(95%CI:1.11-1.43)。

核心结论

  • 合理的填补方法测试缺失数据所致偏倚风险,使高比例最初提示获益的研究其95%CI跨过无效线。
  • 缺失数据比例越大且治疗效应越小,CI越可能跨过无效线。

研究设计与样本

  • 选取100篇系统评价,共纳入1298项随机对照试验,这些系统评价包含对连续患者报告疗效结局有统计学显著效应的Meta分析。
  • 应用基于GRADE的四种逐渐严格的填补策略及三种替代方法处理研究者已填补缺失数据的研究,并行Firth逻辑回归分析。

主要发现

  • 三种处理已填补数据的方法结果相似。
  • 最不严格填补策略下,95%CI跨过无效线的Meta分析比例低于4%。
  • 次严格策略下,CI跨过无效线的比例增至47.9%;再次严格策略下升至53.1%,最严格策略下为54.2%。
  • Firth逻辑回归显示,缺失数据每增加1%,CI跨过无效线的OR为1.23(95%CI:1.11-1.43);治疗效应每增加1个标准化均数差,CI跨过无效线的OR为0.70(95%CI:0.39-0.91)。
  • 数据库类型(Cochrane与非Cochrane)及随访时长与CI跨过无效线均无关。

关键数值与推荐

  • 最不严格策略下95%CI跨过无效线的比例<4%。
  • 次严格策略下95%CI跨过无效线的比例为47.9%。
  • 再次严格策略下95%CI跨过无效线的比例为53.1%,最严格策略下为54.2%。
  • 缺失数据每增加1%,CI跨过无效线的OR为1.23(95%CI:1.11-1.43)。
  • 治疗效应每增加1个标准化均数差,CI跨过无效线的OR为0.70(95%CI:0.39-0.91)。

临床怎么用

  • 系统评价作者可考虑正式检验其结果对缺失数据的稳健性(作者建议)。
  • 解释系统评价结果时需充分考虑缺失数据的数量(作者认为)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Missing outcome data (hereafter referred to as "missing data," typically due to loss to follow-up) is a major problem in randomized controlled trials (RCTs) and systematic reviews of RCTs. While prior work has examined the impact of missing binary outcomes, the influence of missing continuous patient-reported outcome measures (PROMs) on pooled effect estimates remains poorly understood. We therefore assessed the risk of bias introduced by missing data in systematic reviews of PROMs. STUDY DESIGN AND SETTING: We selected a representative sample of 100 systematic reviews that included meta-analyses reporting a statistically significant effect on a continuous patient-reported efficacy outcome. We applied four increasingly stringent imputation strategies based on the grading of recommendations assessment, development, and evaluation (GRADE) approach, along with three alternative approaches for handling studies in which investigators had already imputed results for missing data. We also conducted Firth logistic regression analyses to identify factors associated with crossing the null after imputation. RESULTS: Results from 100 systematic reviews that included 1298 RCTs proved similar across all three approaches to addressing imputed data. Using the least stringent strategy for imputing missing data, the percentage of meta-analyses in which the 95% CI crossed the null proved under 4%. Applying the next most stringent strategy, the percentage of CIs that crossed the null increased to 47.9%. Percentages crossing the null increased only marginally for the two most stringent approaches, crossing up to 53.1% in the next most stringent and 54.2% in the most stringent. Firth logistic regression identified two significant predictors of crossing the null after imputation: a higher average missing data (odds ratio [OR] 1.23, 95% CI: 1.11-1.43 per 1% increase in missing data) and a larger magnitude of the treatment effect, which was associated with lower odds of crossing the null (OR 0.70, 95% CI: 0.39-0.91 per 1 standardized mean difference increase). Neither database type (Cochrane vs. non-Cochrane) nor duration of follow-up proved associated with CI crossing the null. CONCLUSION: A plausible imputation approach to test the potential risk of bias as a result of missing data in studies addressing treatment effects on PROMs resulted in 95% CIs in a high proportion of studies initially suggesting benefit crossing the null. The greater the proportion of missing data and the smaller the treatment effect, the more likely the CI crossed the null. Systematic review authors may consider formally testing the robustness of their results with respect to missing data. PLAIN LANGUAGE SUMMARY: When studies included in a systematic review have missing outcome data, the study results may be biased and therefore misleading. If there is not much missing data, this is not a problem. If there is lots of missing data, it can be a big problem. Researchers have suggested ways of highlighting how much of a problem missing data represents. This study compared four methods for handling missing data in continuous outcomes that measures patients' experience, we call these patient-reported outcomes. We found that reasonable approaches to assessing the possible bias from missing data in systematic reviews and meta-analyses frequently highlight substantial problems and suggest that more guarded conclusions may be warranted in systematic reviews. These findings highlight the importance of fully considering the amount of missing data when interpreting the results of systematic reviews.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Shen Y, Li Z, Gu X, et al. An imputation study shows that missing outcome data can substantially bias pooled estimates in systematic reviews of patient-reported outcomes. J Clin Epidemiol. 2025. PMID: 41461360. doi:10.1016/j.jclinepi.2025.112120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。